MultiOmic is a next-generation precision medicine company, applying systems biology to discover therapeutics and diagnostics for treating metabolic syndrome patients — the world’s largest healthcare burden. Using our unique combination of data science and experimental biology expertise, we identify patient subpopulations having their own distinct molecular-level disease drivers. We use these insights to generate therapeutic R&D programmes with corresponding biomarkers. These patient-stratifying biomarkers enable shorter and smaller clinical trials and inherently higher success rates for our therapeutic assets
Metabolic syndrome refers to a set of lifestyle and age-related risk factors (dysglycemia, hypertension, dyslipidemia and excess weight) that lead to multiple serious medical conditions — atherosclerotic cardiovascular disease, type 2 diabetes, chronic kidney disease, non-alcoholic fatty liver and polycystic ovary syndrome. These conditions consume $2 trillion of global healthcare costs annually (forecast >$5.5 trillion by 2040). It is a 1.6x larger market than oncology, yet attracts only 40% of the investment
CHRONIC KIDNEY DISEASE
NON-ALCOHOLIC FATTY LIVER
Currently-available treatments for patients with metabolic syndrome-derived medical conditions are “one-size-fits-all”, addressing only the risk factors and symptoms. By targeting the unique set of molecular disease drivers that afflict specific patient subpopulations, we treat the root causes of disease progression. This “precision medicine” approach has been a huge success in cancer using genetics as a basis for differentiating disease variants. But our target diseases are chronic and driven to a large extent by life experience since birth—we need to look at longitudinal clinical data in combination with genetics, epigenetics, proteomics and metabolomics to be able to capture the accumulated effects of these environmental factors over time
METABOLIC SYNDROME PANDEMIC
please view sidebar for data sources.
WHAT WE DO
MULTI Omic ANalysis.
How someone's genes predispose disease and influence drug response
How ageing and external factors affect gene expression
Which genes are actually expressed i.e. instructions generated to make proteins
Which proteins are actually produced
Which byproducts of metabolism are generated
Which gut bacteria influence metabolism
UNDERSTANDING CHRONIC DISEASE BIOLOGY
EXPERTS IN THEIR FIELDS
Co-founder & CEO
30+ years in biopharma & healthcare, focusing on R&D management, B2B partnerships and value creation strategy. Has engaged with over 100 organizations in biopharma, medical technology and healthcare. Published authority on biopharma R&D partnerships and biotech business models
CHIEF TECHNOLOGY OFFICER
Deep technical capabilities, strong academic network and author of multiple scientific papers on system biology modeling of cardiometabolic diseases. Most recent prior role was leading a data science team at a Boston-based biotech that was acquired for >$2 billion
CHIEF SCIENCE OFFICER
Forbes 30 under 30. Founded The Longevity Labs, whose nutraceutical is now marketed in >14 countries including USA, exited after 3 years. Leadership experience with two other startups in cancer genomics and AI-enabled robotics
Celia Antonio Schell
CHIEF OPERATING OFFICER
14 years experience in clinical research at Novartis and ICON. Recently managed a global Phase III clinical trial of >7,000 cardiovascular patients across 43 countries
Lead DATA SCIENTIST
Accomplished systems biology modeler. Most recently at the European Bioinformatics Institute. Prior to this, conducted academic research including journal papers on systems biology modeling of atherosclerosis
LEAD DISEASE BIOLOGIST
Award-winning renal biologist. Has taken a novel therapeutic from unvalidated target to development candidate for Phase I. Previously at a UK biotech managing drug discovery assays and preclinical development studies
CHIEF OF STAFF & FINANCE MANAGER
Broad experience base of international collaborative activities. Product manager in a B2B financial data & solutions provider. Project manager in an energy & fintech business. Founded & exited own business
Experienced at analyzing and interpreting multi-omic patient and in vitro/in vivo data. Previously in the translational medicine data science team at Benevolent AI
BUSINESS DEVT. & ALLIANCE MGMT.
Analyst working across the bioscience and business interface with Master’s degree in Bioscience Entrepreneurship and Bachelor’s degree in biochemistry. Previous experience working in a range of healthcare-centred roles, spanning project support in primary care training to life sciences public relations
PARTNERSHIPS & CORPORATE DEVT.
Analyst working at the cross-section of business and bioscience, with an MSc in Bioscience Entrepreneurship and a BSc in Biomedical Sciences. Prior experience includes working in bioscience SMEs across marketing and business development functions, as well as pharmaceutical R&D
Experienced at analyzing high-dimensional omics datasets and building bioinformatics pipelines. Previously a postdoc at Imperial College London
SCIENCE & BUSINESS ANALYST
Previously interned at Immunocore, AstraZeneca and the Wellcome Sanger Institute
MULTIOMIC HEALTH IS A MEMBER OF
Want to be a part of our team?
Got a partnership in mind?
Get in touch with us and know more about how we are changing the face of healthcare.
Multiomic Health Limited is a registered UK company
25 City Road, Shoreditch, London, EC1Y 1AA